Omega-3 supplement to slow early dry macular degeneration
Part of Eyes & vision clinical trials.
This trial studies whether taking omega-3 fatty acids can slow the worsening of dry age-related macular degeneration (AMD) in people with early or intermediate disease. It may help by testing if omega-3 changes how the retina changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with dry AMD at an early or intermediate stage (based on retinal photos).
- Your eye test photos show small-to-medium drusen (early) or larger drusen (intermediate).
- You must be willing to stop omega-3 fatty acids, choline, and astaxanthin supplements before joining.
- You must be able to attend follow-up visits for at least 3 months and be willing to sign consent.
- You can’t have certain other eye problems, like wet AMD (choroidal neovascularization) or geographic atrophy, or high myopia.
- You should not have had cataract surgery in the last 3 months, and your eye pressure must be 26 mmHg or lower.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking daily supplements of lutein, zeaxanthin, and fish oil can improve the protective pigment in your eyes. It may help people with low macular pigment and good vision who are not already taking high doses of these nutrients.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
This study tests whether improving your diet through online meetings can help slow early age-related macular degeneration (AMD), a condition affecting vision. You'll meet with a counselor remotely to make healthier food choices.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.